[go: up one dir, main page]

ATE215829T1 - Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus - Google Patents

Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus

Info

Publication number
ATE215829T1
ATE215829T1 AT97934838T AT97934838T ATE215829T1 AT E215829 T1 ATE215829 T1 AT E215829T1 AT 97934838 T AT97934838 T AT 97934838T AT 97934838 T AT97934838 T AT 97934838T AT E215829 T1 ATE215829 T1 AT E215829T1
Authority
AT
Austria
Prior art keywords
heparin
chitosan
herpes virus
prevent
infections caused
Prior art date
Application number
AT97934838T
Other languages
English (en)
Inventor
Olle Larm
Marcus Back
Tomas Bergstroem
Original Assignee
Medicarb Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicarb Ab filed Critical Medicarb Ab
Application granted granted Critical
Publication of ATE215829T1 publication Critical patent/ATE215829T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT97934838T 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus ATE215829T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning
PCT/SE1997/001320 WO1998005341A1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus

Publications (1)

Publication Number Publication Date
ATE215829T1 true ATE215829T1 (de) 2002-04-15

Family

ID=20403528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934838T ATE215829T1 (de) 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus

Country Status (13)

Country Link
US (1) US6207653B1 (de)
EP (1) EP0930885B1 (de)
JP (1) JP2000515543A (de)
CN (1) CN1227493A (de)
AT (1) ATE215829T1 (de)
AU (1) AU705189B2 (de)
CA (1) CA2261742A1 (de)
DE (1) DE69711897T2 (de)
DK (1) DK0930885T3 (de)
ES (1) ES2174273T3 (de)
NZ (1) NZ333925A (de)
SE (1) SE507028C2 (de)
WO (1) WO1998005341A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508760C2 (sv) 1997-04-29 1998-11-02 Medicarb Ab Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur
WO2001013910A2 (en) * 1999-08-25 2001-03-01 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
EP1774971A1 (de) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Nanopartikel enthaltend Chitosan und Heparin
RU2432187C2 (ru) 2005-12-13 2011-10-27 ЭксТера Медикал ЛЛС Метод экстракорпорального удаления из крови патогенных микробов, клеток воспаления или белков воспаления
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
CL2008000156A1 (es) * 2008-01-18 2008-08-01 Igloo Zone Chile S A Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
JP2012529506A (ja) * 2009-06-10 2012-11-22 エーエクスセラ アクチエボラグ 粘膜炎治療用組成物の使用
CA2782311C (en) 2009-12-01 2017-06-27 Robert S. Ward Method for removing cytokines from blood with surface immobilized polysaccharides
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
KR101800773B1 (ko) * 2010-04-07 2017-11-23 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 보존안정성이 우수한 s-아데노실-l-메티오닌 함유 건조 효모 조성물 및 그 제조 방법
WO2011142484A1 (ja) * 2010-05-14 2011-11-17 株式会社日本触媒 ポリアルキレンイミンを含むウイルス感染症治療薬
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
ES2647577T3 (es) 2012-06-13 2017-12-22 Exthera Medical Corporation Uso de heparina y carbohidratos para tratar el cáncer
WO2014209782A1 (en) 2013-06-24 2014-12-31 Exthera Medical Corporation Blood filtration system containing mannose coated substrate
CA2928866C (en) 2013-11-08 2021-11-09 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
MX2016013873A (es) 2014-04-24 2017-03-09 Exthera Medical Corp Metodo para eliminar bacterias de la sangre usando alta velocidad de flujo.
US10857283B2 (en) 2014-09-22 2020-12-08 Exthera Medical Corporation Wearable hemoperfusion device
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2020231830A1 (en) 2019-05-16 2020-11-19 Exthera Medical Corporation Method for modulating endothelial glycocalyx structure
US20230381217A1 (en) * 2020-10-14 2023-11-30 Medoderm Gmbh Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease
WO2023044132A2 (en) * 2021-09-17 2023-03-23 Shawn Walker Use of chitosan complexes or compositions to reduce infiltration of environmental factors into the brain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) * 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
EP0240098A3 (de) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
AU1052492A (en) 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent

Also Published As

Publication number Publication date
DK0930885T3 (da) 2002-05-06
DE69711897D1 (de) 2002-05-16
WO1998005341A1 (en) 1998-02-12
SE507028C2 (sv) 1998-03-16
AU705189B2 (en) 1999-05-20
NZ333925A (en) 2000-07-28
EP0930885A1 (de) 1999-07-28
SE9602931L (sv) 1998-02-07
JP2000515543A (ja) 2000-11-21
AU3791197A (en) 1998-02-25
CN1227493A (zh) 1999-09-01
US6207653B1 (en) 2001-03-27
EP0930885B1 (de) 2002-04-10
DE69711897T2 (de) 2002-08-22
ES2174273T3 (es) 2002-11-01
CA2261742A1 (en) 1998-02-12
SE9602931D0 (sv) 1996-08-06

Similar Documents

Publication Publication Date Title
ATE215829T1 (de) Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
CA2194976A1 (en) Wound healing agent
DE69428268D1 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
BR9306040A (pt) Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69327731D1 (de) Verfahren zur herstellung einer schutzsperre gegen virus
ATE94760T1 (de) Sulfatierte vinylpolymere in praeparaten zur behandlung von retroviralen infektionen.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
BR9406548A (pt) Composto para emprego como produto farmacêutico composto para emprego no tratamento ou prevenção de câncer e pré-câncer ou de doenças causadas por infecçao viral composto para emprego no tratamento ou prãvençao de câncer ou de pré-câncer composto para emprego no tratamento ou prevenção de doenças causadas por infecção viral composiçao farmacêutica processo para tratar doenças causadas por infecção viral processo de tratamento de câncer ou pré-câncer composto de ácido clorobenzenossulfônico ou ni
DE69003960D1 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
ATE316789T1 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
ATE204476T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
DE69925312D1 (de) Bupropion zur behandlung von viralen erkrankungen
SE9303612D0 (sv) New use
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
DK120892D0 (da) Treatment and prophylaxis of diseases caused by parasites, fungi or bacteria
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
UA30950A (uk) Спосіб лікування гнійно-запальних захворювань щелепо-лицьової області

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee